• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Cooperation of the HDAC inhibitor vorinostat and radiation in metastatic neuroblastoma: efficacy and underlying mechanisms.组蛋白去乙酰化酶抑制剂伏立诺他联合放疗治疗转移性神经母细胞瘤：疗效和潜在机制。
Cancer Lett. 2011 Jul 28;306(2):223-9. doi: 10.1016/j.canlet.2011.03.010. Epub 2011 Apr 16.
2
Vorinostat, a histone deacetylase inhibitor, enhances the response of human tumor cells to ionizing radiation through prolongation of gamma-H2AX foci.伏立诺他，一种组蛋白去乙酰化酶抑制剂，通过延长γ-H2AX焦点增强人类肿瘤细胞对电离辐射的反应。
Mol Cancer Ther. 2006 Aug;5(8):1967-74. doi: 10.1158/1535-7163.MCT-06-0022.
3
Vorinostat enhances the radiosensitivity of a breast cancer brain metastatic cell line grown in vitro and as intracranial xenografts.伏立诺他增强了体外培养的乳腺癌脑转移细胞系以及颅内异种移植瘤的放射敏感性。
Mol Cancer Ther. 2009 Jun;8(6):1589-95. doi: 10.1158/1535-7163.MCT-09-0038. Epub 2009 Jun 9.
4
Efficacy of class I and II vs class III histone deacetylase inhibitors in neuroblastoma.I 类和 II 类与 III 类组蛋白去乙酰化酶抑制剂在神经母细胞瘤中的疗效比较。
J Pediatr Surg. 2012 Jun;47(6):1267-71. doi: 10.1016/j.jpedsurg.2012.03.039.
5
A novel small molecule hybrid of vorinostat and DACA displays anticancer activity against human hormone-refractory metastatic prostate cancer through dual inhibition of histone deacetylase and topoisomerase I.一种新型小分子伏立诺他和 DACA 的杂合体通过双重抑制组蛋白去乙酰化酶和拓扑异构酶 I 显示出对人激素难治性转移性前列腺癌的抗癌活性。
Biochem Pharmacol. 2014 Aug 1;90(3):320-30. doi: 10.1016/j.bcp.2014.06.001. Epub 2014 Jun 7.
6
Histone deacetylase inhibitors radiosensitize human melanoma cells by suppressing DNA repair activity.组蛋白去乙酰化酶抑制剂通过抑制DNA修复活性使人类黑色素瘤细胞对辐射敏感。
Clin Cancer Res. 2005 Jul 1;11(13):4912-22. doi: 10.1158/1078-0432.CCR-04-2088.
7
Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, enhances radiosensitivity and suppresses lung metastasis in breast cancer in vitro and in vivo.辛二酰苯胺异羟肟酸，一种组蛋白去乙酰化酶抑制剂，在体外和体内均可增强乳腺癌的放射敏感性并抑制肺转移。
PLoS One. 2013 Oct 10;8(10):e76340. doi: 10.1371/journal.pone.0076340. eCollection 2013.
8
Histone Deacetylase (HDAC) Inhibition Induces IκB Kinase (IKK)-dependent Interleukin-8/CXCL8 Expression in Ovarian Cancer Cells.组蛋白去乙酰化酶（HDAC）抑制可诱导卵巢癌细胞中依赖IκB激酶（IKK）的白细胞介素-8/CXCL8表达。
J Biol Chem. 2017 Mar 24;292(12):5043-5054. doi: 10.1074/jbc.M116.771014. Epub 2017 Feb 6.
9
Combined inhibition of EZH2 and histone deacetylases as a potential epigenetic therapy for non-small-cell lung cancer cells.EZH2与组蛋白去乙酰化酶的联合抑制作为非小细胞肺癌细胞的一种潜在表观遗传疗法。
Cancer Sci. 2016 Jul;107(7):955-62. doi: 10.1111/cas.12957. Epub 2016 Jun 13.
10
Vorinostat inhibits brain metastatic colonization in a model of triple-negative breast cancer and induces DNA double-strand breaks.伏立诺他在三阴性乳腺癌模型中抑制脑转移定植并诱导DNA双链断裂。
Clin Cancer Res. 2009 Oct 1;15(19):6148-57. doi: 10.1158/1078-0432.CCR-09-1039. Epub 2009 Sep 29.

引用本文的文献

1
Epigenetic drugs in cancer therapy.用于癌症治疗的表观遗传药物。
Cancer Metastasis Rev. 2025 Feb 26;44(1):37. doi: 10.1007/s10555-025-10253-7.
2
Theranostics for Neuroblastoma: Making Molecular Radiotherapy Work Better.神经母细胞瘤的诊疗一体化：让分子放射治疗更有效
J Nucl Med. 2025 Apr 1;66(4):490-496. doi: 10.2967/jnumed.124.269121.
3
Stochasticity of anticancer mechanisms underlying clinical effectiveness of vorinostat.伏立诺他临床疗效背后抗癌机制的随机性。
Heliyon. 2024 Jun 18;10(12):e33052. doi: 10.1016/j.heliyon.2024.e33052. eCollection 2024 Jun 30.
4
Aurora Kinase A inhibition enhances DNA damage and tumor cell death with I-MIBG therapy in high-risk neuroblastoma.在高危神经母细胞瘤中，极光激酶A抑制与I-间碘苄胍疗法联合可增强DNA损伤和肿瘤细胞死亡。
EJNMMI Res. 2024 Jun 13;14(1):54. doi: 10.1186/s13550-024-01112-7.
5
Molecular mechanisms of extracellular-ATP-mediated colorectal cancer progression: Implication of purinergic receptors-mediated nucleocytoplasmic shuttling of HuR.细胞外 ATP 介导电泳大肠癌进展的分子机制：嘌呤能受体介导 HuR 的核质穿梭的意义。
Purinergic Signal. 2024 Dec;20(6):669-680. doi: 10.1007/s11302-024-10021-2. Epub 2024 May 27.
6
Mechanistic Sequence of Histone Deacetylase Inhibitors and Radiation Treatment: An Overview.组蛋白去乙酰化酶抑制剂与放射治疗的作用机制序列：概述
Pharmaceuticals (Basel). 2024 May 8;17(5):602. doi: 10.3390/ph17050602.
7
UBE4B interacts with the ITCH E3 ubiquitin ligase to induce Ku70 and c-FLIPL polyubiquitination and enhanced neuroblastoma apoptosis.UBE4B 与 ITCH E3 泛素连接酶相互作用，诱导 Ku70 和 c-FLIPL 多泛素化，并增强神经母细胞瘤细胞凋亡。
Cell Death Dis. 2023 Nov 13;14(11):739. doi: 10.1038/s41419-023-06252-7.
8
Norepinephrine transporter and vesicular monoamine transporter 2 tumor expression as a predictor of response to I-MIBG in patients with relapsed/refractory neuroblastoma.去甲肾上腺素转运体和囊泡单胺转运体2在肿瘤中的表达作为复发/难治性神经母细胞瘤患者对I-MIBG反应的预测指标。
Pediatr Blood Cancer. 2024 Jan;71(1):e30743. doi: 10.1002/pbc.30743. Epub 2023 Oct 26.
9
Recent advances in epigenetic anticancer therapeutics and future perspectives.表观遗传抗癌疗法的最新进展及未来展望。
Front Genet. 2023 Jan 4;13:1085391. doi: 10.3389/fgene.2022.1085391. eCollection 2022.
10
The paradigm of drug resistance in cancer: an epigenetic perspective.癌症耐药性的范式：表观遗传学视角。
Biosci Rep. 2022 Apr 29;42(4). doi: 10.1042/BSR20211812.

本文引用的文献

1
Histone deacetylase inhibitor induces DNA damage, which normal but not transformed cells can repair.组蛋白去乙酰化酶抑制剂诱导 DNA 损伤，正常细胞而非转化细胞可以修复这种损伤。
Proc Natl Acad Sci U S A. 2010 Aug 17;107(33):14639-44. doi: 10.1073/pnas.1008522107. Epub 2010 Aug 2.
2
Vorinostat, a histone deacetylase inhibitor, combined with pelvic palliative radiotherapy for gastrointestinal carcinoma: the Pelvic Radiation and Vorinostat (PRAVO) phase 1 study.伏立诺他，一种组蛋白去乙酰化酶抑制剂，联合盆腔姑息性放疗治疗胃肠道癌：盆腔放疗和伏立诺他（PRAVO）1 期研究。
Lancet Oncol. 2010 May;11(5):459-64. doi: 10.1016/S1470-2045(10)70058-9. Epub 2010 Apr 6.
3
Vorinostat enhances the radiosensitivity of a breast cancer brain metastatic cell line grown in vitro and as intracranial xenografts.伏立诺他增强了体外培养的乳腺癌脑转移细胞系以及颅内异种移植瘤的放射敏感性。
Mol Cancer Ther. 2009 Jun;8(6):1589-95. doi: 10.1158/1535-7163.MCT-09-0038. Epub 2009 Jun 9.
4
Radiosensitization by SAHA in experimental colorectal carcinoma models-in vivo effects and relevance of histone acetylation status.SAHA对实验性结直肠癌模型的放射增敏作用——体内效应及组蛋白乙酰化状态的相关性
Int J Radiat Oncol Biol Phys. 2009 Jun 1;74(2):546-52. doi: 10.1016/j.ijrobp.2009.01.068.
5
IFN-beta sensitizes neuroblastoma to the antitumor activity of temozolomide by modulating O6-methylguanine DNA methyltransferase expression.干扰素-β通过调节O6-甲基鸟嘌呤DNA甲基转移酶的表达，使神经母细胞瘤对替莫唑胺的抗肿瘤活性敏感。
Mol Cancer Ther. 2008 Dec;7(12):3852-8. doi: 10.1158/1535-7163.MCT-08-0806. Epub 2008 Dec 3.
6
Radiolabeled metaiodobenzylguanidine for the treatment of neuroblastoma.用于治疗神经母细胞瘤的放射性标记间碘苄胍
Nucl Med Biol. 2008 Aug;35 Suppl 1(Suppl 1):S35-48. doi: 10.1016/j.nucmedbio.2008.05.002.
7
HDAC inhibitor PCI-24781 decreases RAD51 expression and inhibits homologous recombination.组蛋白去乙酰化酶抑制剂PCI-24781可降低RAD51表达并抑制同源重组。
Proc Natl Acad Sci U S A. 2007 Dec 4;104(49):19482-7. doi: 10.1073/pnas.0707828104. Epub 2007 Nov 27.
8
In vivo bioluminescence imaging for early detection and monitoring of disease progression in a murine model of neuroblastoma.在神经母细胞瘤小鼠模型中，用于疾病进展早期检测和监测的体内生物发光成像。
J Pediatr Surg. 2007 Jul;42(7):1172-9. doi: 10.1016/j.jpedsurg.2007.02.027.
9
Phase I and pharmacokinetic study of vorinostat, a histone deacetylase inhibitor, in combination with carboplatin and paclitaxel for advanced solid malignancies.组蛋白去乙酰化酶抑制剂伏立诺他联合卡铂和紫杉醇治疗晚期实体恶性肿瘤的I期和药代动力学研究
Clin Cancer Res. 2007 Jun 15;13(12):3605-10. doi: 10.1158/1078-0432.CCR-07-0162. Epub 2007 May 17.
10
Clonogenic assay of cells in vitro.体外细胞克隆形成试验。
Nat Protoc. 2006;1(5):2315-9. doi: 10.1038/nprot.2006.339.

组蛋白去乙酰化酶抑制剂伏立诺他联合放疗治疗转移性神经母细胞瘤：疗效和潜在机制。

Cooperation of the HDAC inhibitor vorinostat and radiation in metastatic neuroblastoma: efficacy and underlying mechanisms.

机构信息

Department of Neurology, University of California, San Francisco, 505 Parnassus Avenue, San Francisco, CA 94143-0106, USA.

出版信息

Cancer Lett. 2011 Jul 28;306(2):223-9. doi: 10.1016/j.canlet.2011.03.010. Epub 2011 Apr 16.

DOI:10.1016/j.canlet.2011.03.010
PMID:21497989
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3244077/
Abstract

Histone deacetylase (HDAC) inhibitors can radiosensitize cancer cells. Radiation is critical in high-risk neuroblastoma treatment, and combinations of HDAC inhibitor vorinostat and radiation are proposed for neuroblastoma trials. Therefore, we investigated radiosensitizing effects of vorinostat in neuroblastoma. Treatment of neuroblastoma cell lines decreased cell viability and resulted in additive effects with radiation. In a murine metastatic neuroblastoma in vivo model vorinostat and radiation combinations decreased tumor volumes compared to single modality. DNA repair enzyme Ku-86 was reduced in several neuroblastoma cells treated with vorinostat. Thus, vorinostat potentiates anti-neoplastic effects of radiation in neuroblastoma possibly due to down-regulation of DNA repair enzyme Ku-86.

摘要

组蛋白去乙酰化酶（HDAC）抑制剂可以使癌细胞对放射敏感。放射治疗在高危神经母细胞瘤的治疗中至关重要，因此提议将 HDAC 抑制剂伏立诺他和放射治疗联合应用于神经母细胞瘤的临床试验。因此，我们研究了伏立诺他在神经母细胞瘤中的放射增敏作用。用伏立诺他处理神经母细胞瘤细胞系会降低细胞活力，并与放射治疗产生相加作用。在一种鼠转移性神经母细胞瘤的体内模型中，与单一治疗方式相比，伏立诺他和放射治疗联合治疗可降低肿瘤体积。用伏立诺他处理几种神经母细胞瘤细胞后，DNA 修复酶 Ku-86 减少。因此，伏立诺他增强了神经母细胞瘤中放射治疗的抗肿瘤作用，可能是由于 DNA 修复酶 Ku-86 的下调。